Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05644-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Shaoyu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Sulfonamides, Antibodies, Bispecific. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Translational Research Grant of NCRCH, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
B/T mixed phenotype acute leukemia (MPAL), which represents only 2–3% of all MPAL cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B/T MPAL have a notably low 3-year survival rate, estimated at 20–40%. The rarity and undercharacterization of B/T MPAL present substantial challenges in identifying an optimal treatment protocol. This report aims to shed light on this issue by presenting a case in which a patient with a complex karyotype was treated using a combination of venetoclax, azacitidine, and blinatumomab. This novel, chemo-free regimen resulted in the patient achieving both hematologic and molecular complete remission, with no severe organ or hematological toxicity observed. Notably, the patient continued to maintain molecular remission for 1 year following the transplantation. Based on these findings, the combination of venetoclax, azacitidine, and blinatumomab could be considered a potential therapeutic approach for B/T MPAL patients, meriting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. xwtang1020@163.com.
- Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, China. xwtang1020@163.com.
Förderung
- National Natural Science Foundation of China
- Translational Research Grant of NCRCH
- Natural Science Foundation of Jiangsu Province
- The Key Science Research Project of Jiangsu Commission of Health
- Frontier Clinical Technical Project of Suzhou Science and Technology plan
- Bethune Charitable Foundation
- Suzhou diagnosis and treatment project of Clinical Key Diseases
- the Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Liu, S., Cui, Q., Li, M., Li, Z., Chen, S., Wu, D., & Tang, X. (2024). Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab. Annals of Hematology. https://doi.org/10.1007/s00277-024-05644-9
Vancouver
Liu S, Cui Q, Li M, Li Z, Chen S, Wu D, et al. Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab. Annals of Hematology. 2024. doi:10.1007/s00277-024-05644-9
BibTeX
@article{Liu2024,
author = {Liu, Shaoyu and Cui, Qingya and Li, Mengyun and Li, Zheng and Chen, Sifan and Wu, Depei and Tang, Xiaowen},
title = {Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05644-9}
}
EUVIMED